Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000331025 | SCV000335345 | uncertain significance | not provided | 2016-10-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001233854 | SCV001406468 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2O; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 | 2022-10-31 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 90 of the POMGNT1 protein (p.Arg90Cys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with POMGNT1-related conditions. ClinVar contains an entry for this variant (Variation ID: 283329). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POMGNT1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000331025 | SCV003811778 | uncertain significance | not provided | 2019-06-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004021130 | SCV005007231 | uncertain significance | Inborn genetic diseases | 2024-01-04 | criteria provided, single submitter | clinical testing | The c.268C>T (p.R90C) alteration is located in exon 4 (coding exon 3) of the POMGNT1 gene. This alteration results from a C to T substitution at nucleotide position 268, causing the arginine (R) at amino acid position 90 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000331025 | SCV005412129 | uncertain significance | not provided | 2024-03-28 | criteria provided, single submitter | clinical testing | BP4 |
Natera, |
RCV001277597 | SCV001464559 | uncertain significance | Muscle eye brain disease | 2020-08-14 | no assertion criteria provided | clinical testing |